Thrombosis and Haemostasis 2020 Editors' Choice Papers

Abstract

In this Editor's choice, we highlight last year's papers from Thrombosis and Haemostasis as well as from its open access companion journal THOpen, which found most resonance among our readers' community, holding promise for mechanistic understanding and improved clinical management in the fields of Thrombosis and Haemostasis. Building on the research investigations from this undoubtedly memorable year may be particularly useful to overcome the current pandemic situation. As it became apparent that coronavirus disease 2019 (COVID-19) was not merely a pulmonary disease but that thrombosis was a key element involved in its severity and complications, the thrombosis research community deployed intensive research efforts in the hope to optimize treatment and/or prophylaxis as well as to decipher the mechanisms and characteristics of COVID-19 thrombosis as rapidly as possible. Due to the urgency of the pandemic development, it was indeed not surprising that publications relating to COVID-19 received by far the most attention in 2020. Unprecedented Research Efforts for Unprecedented TimesEarly on into the pandemic, Lippi and Favaloro 1 proposed the simple D-dimer test for prognosis of COVID-19 severity in a short T&H report which received particular resonance. By using classic coagulation tests together with point-of-care methods such as whole blood thromboelastometry, Spiezia et al 2 further reported specific coagulation alterations, thereby identifying a state of severe hypercoagulability in COVID-19 patients with acute respiratory failure. The systematic review and meta-analysis from Jin et al 3 described the coagulation abnormalities seen in Chinese patients with COVID-19. Boscolo et al comparatively assessed the values of different coagulation tests between patients admitted to internal medicine department versus intensive care unit. 4 Beyond this hypercoagulation state, Violi et al extensively reviewed how clotting variables behave and impact on the severity of COVID-19 along with potential antithrombotic treatment options in COVID-19. 5 Marchandot et al proposed that haemostatic abnormalities could be used to help stage severity of To help thrombosis specialists, investigators, and funders, a truly multidisciplinary collaborative group of experts in disciplines including cardiovascular diseases, hematology, vascular medicine, pharmacy and pharmacology, pulmonary and critical care medicine, laboratory medicine, and health policy joined efforts to form the Global COVID-19 Thrombosis Collaborative Group. Their position paper 7 comprehensively discussed classical anticoagulants, antiplatelet drugs, and their anti-inflammatory mechanisms and also agents that modulate inflammation and may thus help to mitigate thromboinflammation. While a panel of experts from China and Europe published a consensus statement with practical guidelines for the prevention and treatment of venous thromboembolism (VTE) associated with COVID-19, 8 Grandmaison et al highlighted the benefits of systematic VTE screening in COVID-19 patients. 9...

A Happy New Year 2024 from Thrombosis and Haemostasis!

“…With our traditional January Editorial and Editors' Choice, 1 we are delighted to welcome you in the New Year! May it be filled with fresh challenges and developments!…”

A Happy New Year 2023 from Thrombosis and Haemostasis

“…As with our traditional new year's message, we aim to summarize our journey in the last year and look forward to 2023. [1][2][3][4] Another year has quickly passed, and as we emerge into more (three-dimensional) in-person meetings rather than the two-dimensional virtual meetings of various platforms, the journal also continues to grow.…”

“…As with our traditional new year's message, we aim to summarize our journey in the last year and look forward to 2023. 1 2 3 4…”

Thrombosis and Haemostasis 2021 Editors' Choice Papers

“…As in the precedent year, the 2021 COVID-19 pandemic situation has dictated the pace and direction of our research and clinical management efforts which, although not exclusively, is well reflected by this years' Editor's Choice contents. [1][2][3][4] At the end of 2020, we published a Theme Issue dedicated to COVID-19 as a guide to better comprehend newly identified vascular and inflammatory mechanistic aspects of the disease, 5 its hypercoagulation state, 6 and clinical implications for vascular patients with COVID-19. 7,8 To address the rapidly evolving situation and following a first consensus paper, 9 we were pleased to publish an interesting discussion manuscript by the VAS investigators on the need for a more integrated and global strategy to COVID-19, providing a useful overview of public health approaches consideration and the next steps necessary to best manage the pandemic.…”